Early Phase 1
N=103
Leptin Infusion and Endothelial Vasomotor Response
Endothelial Dysfunction · Obesity · Vasodilation · Venous Occlusion Plethysmography
Bottom Line
View on ClinicalTrials.gov: NCT04374500 ↗Enrolled (actual)
103
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: Forearm Blood-flow (FBF) — 1.75; 3.1; NA; NA ml/100 mg tissue/min
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- Leptin infusion plus vasodilators in healthy men (Drug); Leptin infusion in healthy men (Drug); Vasodilators in CAD patients (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Stefan Soderberg
- Primary completion
- Oct 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Forearm Blood-flow (FBF) |
1.75; 3.1; NA; NA; 3.4; NA | — |
| SECONDARY Release of Fibrinolytic Variables (Tissue Plasminogen Activator [tPA] and Plasminogen Activator Inhibitor-1 [PAI-1]) |
0.56; 0.91; NA; NA; 0.73; NA | — |
| SECONDARY Leptin |
186.2; 13.1; NA; NA; 3.4; NA | — |
| SECONDARY Systolic Blood Pressure |
140; 134; NA; NA; 136; NA | — |
| SECONDARY Heart Rate |
59; 66; NA; NA; 66; NA | — |
Summary
Adipose tissue is an active endocrine organ producing several hormones with circulatory and metabolic effects. In 1994, the hormone leptin was discovered. The lack of this hormone explained extreme obesity in rare patients and parenteral substitution restored body weight and metabolic disturbances. It was however soon discovered that most humans had too high levels which were related to development of cardiovascular diseases and diabetes. It was hypothesised that leptin induced vessel dysfunction which could explain this association.
In this study, we wanted to examine the association between leptin and vessel function by using the venous occlusion plethysmography method. We used three protocols to evaluate this association.
First protocol. In ten healthy males, leptin was infused locally in the forearm and forearm blood flow (FBF) was measured.
Second protocol. In ten healthy males, leptin or normal saline was infused locally in the forearm and FBF was measured. Concomitantly, four vasodilatators were infused locally in the forearm in a randomised order and the response (blood flow and fibrinolysis) was measured.
Third protocol. In eighty-three patients with known coronary artery disease, three vasodilators were infused locally in the forearm in a random order and response (FBF and fibrinolysis) was measured. The response was related to endogenous leptin levels.
The two first protocols were performed in Umeå, Sweden whereas the third was performed in Edinburgh, UK, all in 2006.
Eligibility Criteria
Inclusion criteria protocol 1 and 2;
- Healthy male
- No regular medication
- Non-smoking
- Abstain from alcohol for 24 hours and from food, tobacco and caffeine-containing drinks for at least 4 hours before each study visit
Inclusion criteria protocol 3;
- Established coronary artery disease
- Stable angina pectoris
- Documented ≥ 50% stenosis of at least one major epicardial coronary vessel
Exclusion criteria protocol 3;
- Coronary revascularisation within three months
- Diabetes mellitus
- Cardiac failure (ejection fraction 190 mmHg
Data sourced from ClinicalTrials.gov (NCT04374500). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.